Asset Details
Do you wish to reserve the book?
Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\/Authors' Reply to Harpaz et al. Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\/Authors' Reply to Harpaz et al. Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\
Do you wish to request the book?
Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\/Authors' Reply to Harpaz et al. Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\/Authors' Reply to Harpaz et al. Comment on: \Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance\
2015
Overview
Norén et al. argue that signal detection is fundamentally a prognostic activity. [...]evaluation strategies should aim to emulate a prospective analysis of signal detection in lieu of a commonly applied yet unsatisfactory approach of retrospective analysis based on well established associations such as those comprising the Observational Medical Outcome Partnership (OMOP) [2] and EUADR benchmarks [3]. [...]the status of a recently labeled ADR (positive control in some benchmarks) may be revised based on new refuting evidence. [...]the increased level of uncertainty associated with experiments based on such recently labeled or emerging ADRs cannot be ignored. [...]consideration of timeliness does not eliminate the need to distinguish between emerging and established adverse drug reactions; we would not recommend a comparison of statistical signal detection methods based on how early in the post-marketing phase they signalled adverse drug reactions that were known already from pre-marketing clinical trials.
Publisher
Springer Nature B.V
